Literature DB >> 21118815

Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II.

Paul Verbruggen1, Marius Ruf, Gjon Blakqori, Anna K Överby, Martin Heidemann, Dirk Eick, Friedemann Weber.   

Abstract

La Crosse encephalitis virus (LACV) is a mosquito-borne member of the negative-strand RNA virus family Bunyaviridae. We have previously shown that the virulence factor NSs of LACV is an efficient inhibitor of the antiviral type I interferon system. A recombinant virus unable to express NSs (rLACVdelNSs) strongly induced interferon transcription, whereas the corresponding wt virus (rLACV) suppressed it. Here, we show that interferon induction by rLACVdelNSs mainly occurs through the signaling pathway leading from the pattern recognition receptor RIG-I to the transcription factor IRF-3. NSs expressed by rLACV, however, acts downstream of IRF-3 by specifically blocking RNA polymerase II-dependent transcription. Further investigations revealed that NSs induces proteasomal degradation of the mammalian RNA polymerase II subunit RPB1. NSs thereby selectively targets RPB1 molecules of elongating RNA polymerase II complexes, the so-called IIo form. This phenotype has similarities to the cellular DNA damage response, and NSs was indeed found to transactivate the DNA damage response gene pak6. Moreover, NSs expressed by rLACV boosted serine 139 phosphorylation of histone H2A.X, one of the earliest cellular reactions to damaged DNA. However, other DNA damage response markers such as up-regulation and serine 15 phosphorylation of p53 or serine 1524 phosphorylation of BRCA1 were not triggered by LACV infection. Collectively, our data indicate that the strong suppression of interferon induction by LACV NSs is based on a shutdown of RNA polymerase II transcription and that NSs achieves this by exploiting parts of the cellular DNA damage response pathway to degrade IIo-borne RPB1 subunits.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21118815      PMCID: PMC3030371          DOI: 10.1074/jbc.M110.154799

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

Review 1.  Innate recognition of viruses.

Authors:  Andreas Pichlmair; Caetano Reis e Sousa
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

2.  Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.

Authors:  Nathan P Gomes; Glen Bjerke; Briardo Llorente; Stephanie A Szostek; Beverly M Emerson; Joaquin M Espinosa
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

Review 3.  Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response.

Authors:  John Hiscott
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-13       Impact factor: 7.638

Review 4.  Transcription of cloned eukaryotic ribosomal RNA genes.

Authors:  B Sollner-Webb; J Tower
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

Review 5.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Control of inducible gene expression by signal-dependent transcriptional elongation.

Authors:  Diana C Hargreaves; Tiffany Horng; Ruslan Medzhitov
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

Review 7.  Mediator complexes and eukaryotic transcription regulation: an overview.

Authors:  Amelia Casamassimi; Claudio Napoli
Journal:  Biochimie       Date:  2007-08-11       Impact factor: 4.079

8.  Activation of MDA5 requires higher-order RNA structures generated during virus infection.

Authors:  Andreas Pichlmair; Oliver Schulz; Choon-Ping Tan; Jan Rehwinkel; Hiroki Kato; Osamu Takeuchi; Shizuo Akira; Michael Way; Giampietro Schiavo; Caetano Reis e Sousa
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts.

Authors:  Gjon Blakqori; Sophie Delhaye; Matthias Habjan; Carol D Blair; Irma Sánchez-Vargas; Ken E Olson; Ghassem Attarzadeh-Yazdi; Rennos Fragkoudis; Alain Kohl; Ulrich Kalinke; Siegfried Weiss; Thomas Michiels; Peter Staeheli; Friedemann Weber
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

10.  Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction.

Authors:  Matthias Habjan; Ida Andersson; Jonas Klingström; Michael Schümann; Arnold Martin; Petra Zimmermann; Valentina Wagner; Andreas Pichlmair; Urs Schneider; Elke Mühlberger; Ali Mirazimi; Friedemann Weber
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

View more
  47 in total

1.  Induction of DNA damage signaling upon Rift Valley fever virus infection results in cell cycle arrest and increased viral replication.

Authors:  Alan Baer; Dana Austin; Aarthi Narayanan; Taissia Popova; Markus Kainulainen; Charles Bailey; Fatah Kashanchi; Friedemann Weber; Kylene Kehn-Hall
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

2.  The interactome of the human respiratory syncytial virus NS1 protein highlights multiple effects on host cell biology.

Authors:  Weining Wu; Kim C Tran; Michael N Teng; Kate J Heesom; David A Matthews; John N Barr; Julian A Hiscox
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Generation of Recombinant Oropouche Viruses Lacking the Nonstructural Protein NSm or NSs.

Authors:  Natasha L Tilston-Lunel; Gustavo Olszanski Acrani; Richard E Randall; Richard M Elliott
Journal:  J Virol       Date:  2015-12-23       Impact factor: 5.103

4.  Visualizing production of beta interferon by astrocytes and microglia in brain of La Crosse virus-infected mice.

Authors:  Carsten Kallfass; Andreas Ackerman; Stefan Lienenklaus; Siegfried Weiss; Bernd Heimrich; Peter Staeheli
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

5.  Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome.

Authors:  Rima Benferhat; Thibaut Josse; Benoit Albaud; David Gentien; Zeyni Mansuroglu; Vasco Marcato; Sylvie Souès; Bernard Le Bonniec; Michèle Bouloy; Eliette Bonnefoy
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

6.  Attenuation of bunyamwera orthobunyavirus replication by targeted mutagenesis of genomic untranslated regions and creation of viable viruses with minimal genome segments.

Authors:  Béryl Mazel-Sanchez; Richard M Elliott
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

7.  Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling.

Authors:  Michaela Weber; Ali Gawanbacht; Matthias Habjan; Andreas Rang; Christoph Borner; Anna Mareike Schmidt; Sophie Veitinger; Ralf Jacob; Stéphanie Devignot; Georg Kochs; Adolfo García-Sastre; Friedemann Weber
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

8.  Mouse embryonic stem cells are deficient in type I interferon expression in response to viral infections and double-stranded RNA.

Authors:  Ruoxing Wang; Jundi Wang; Amber M Paul; Dhiraj Acharya; Fengwei Bai; Faqing Huang; Yan-Lin Guo
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

9.  Activation of the innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein SARM1, leading to neuronal death.

Authors:  Piyali Mukherjee; Tyson A Woods; Roger A Moore; Karin E Peterson
Journal:  Immunity       Date:  2013-03-14       Impact factor: 31.745

10.  Abortively Infected Astrocytes Appear To Represent the Main Source of Interferon Beta in the Virus-Infected Brain.

Authors:  Cathleen Pfefferkorn; Carsten Kallfass; Stefan Lienenklaus; Julia Spanier; Ulrich Kalinke; Martina Rieder; Karl-Klaus Conzelmann; Thomas Michiels; Peter Staeheli
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.